1. Scrip
  2. >>Rare Diseases

Belgium's Argenx Advances On More Positive Efgartigimod Data

Filing Imminent For Promising Myasthenia Gravis Therapy

 
• By Kevin Grogan

Argenx's efgartigimod, an antibody fragment that blocks FcRn, looks most likely to be the first drug to challenge Alexion's Soliris in the myasthenia gravis market after the company presented more positive data from the ADAPT trial.

Documents
Positive data keeps piling up for efgartigimod • Source: Shutterstock

With a US filing for efgartigimod imminent, Belgian biotech argenx N.V. has presented more positive data on the potential first-in-class product which has been touted as a future standard of care for the rare autoimmune disease myasthenia gravis.

Additional data from the previously reported Phase III ADAPT trial which enrolled patients who were either acetylcholine receptor-antibody (AChR-A) positive or negative have been presented at the Myasthenia Gravis Foundation of America scientific session, showing impressive responder rates for efgartigimod on two measures of efficacy, the myasthenia gravis activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) scores

More from Rare Diseases

Lundbeck Lifted By Leap In Migraine Therapy Sales

 
• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

 
• By Sushmita Panda

The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.

More from Scrip

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.